EICHOR
● Not Yet Recruiting
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
Condition: Myeloma Multiple · Sponsor: Centre Hospitalier Universitaire de Saint Etienne
About this study
The BELAMI trial is an open label, multicenter, phase 2 study for patients with MM who relapsed following BCMA-directed CAR-T cells or bispecific antibodies with a Phase Ib Safety run-in. The primary hypothesis of this study is that a combination of ADC targeting BCMA and CELMoD will be efficient for these patients.
This description comes directly from the study's public registry record.
Talk to the study team
Emilie CHALAYER, MD · (0)4 77 82 28 14 · Emilie.Chalayer2@chu-st-etienne.fr
Always discuss trial participation with your own doctor first.
Locations (30)
| Centre Hospitalier Universitaire | Amiens, France | — |
| Centre Hospitalier Universitaire | Angers, France | — |
| Centre Hospitalier Universitaire | Annecy, France | — |
| Centre Hospitalier D'Argenteuil | Argenteuil, France | — |
| Centre Hospitalier de La Cote Basque | Bayonne, France | — |
| Institut Bergonié | Bordeaux, France | — |
| Centre Hospitalier Universitaire | Brest, France | — |
| Centre Hospitalier Universitaire | Caen, France | — |
| Centre Hospitalier Universitaire | Clermont-Ferrand, France | — |
| Centre Hospitalier Universitaire | Dijon, France | — |
| Centre Hospitalier Universitaire | Grenoble, France | — |
| Centre Hospitalier | Le Mans, France | — |
+ 18 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07612787